Dermatomyositis
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
Drugs by status
Approved for this indication (1)
Phase 4 trials (8)
Phase 3 trials (15)
Phase 2 trials (33)
- pb1023
- methylprednisolone
- denosumab
- apremilast
- eculizumab
- gamma globulin
- ifn-kinoid
- imo-8400
- jbt-101
- methimazole
- mycophenolate
- cyclophosphamide
- tocilizumab
- cd19 car-t cells
- infliximab
- methotrexate
- fludarabine
- sodium thiosulfate
- rituximab
- basiliximab
- isa-51
- siponimod
- bcma-pd1-cart cell
- Zetomipzomib
- enpatoran
- mrna-1273
- glpg3667
- bnt162b2
- argx-117
- deucravacitinib
- +3 more
Phase 1 trials (9)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (18)
- CSL Behring
- Immunex
- Bristol-Myers Squibb
- Astellas
- Octapharma
- Corbus Pharmaceuticals Inc.
- Japan Blood Products Organization
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pennsylvania
- University of Pittsburgh
- Tokyo Medical and Dental University
- University of Cincinnati
- Karolinska Institute
- Janssen Pharmaceutica NV
- University of Genoa
- Charles University
- GNI Group
- Japan Medical Association
Organization Involved with Phase 2 Indications (15)
- Aceragen, Inc/
- Genentech
- Pfizer
- Biogen
- Novartis
- Neovacs
- National Institute of Environmental Health Sciences (NIEHS)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of London
- Indiana University
- Northwestern University
- Tulane University
- Mayo Clinic
- University of Limoges
- Kezar Life Sciences, Inc.
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (3)